A phase I trial to evaluate the HIV-1 SF-2 recombinant p24 subunit vaccine [HIV vaccine; Chiron vaccines] administered as a novel boost in prime-boost vaccination regimens with ALVAC-HIV vCP205 [HIV vaccine vCP205; Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [HIV gp120 vaccine; Chiron Vaccines]

Trial Profile

A phase I trial to evaluate the HIV-1 SF-2 recombinant p24 subunit vaccine [HIV vaccine; Chiron vaccines] administered as a novel boost in prime-boost vaccination regimens with ALVAC-HIV vCP205 [HIV vaccine vCP205; Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [HIV gp120 vaccine; Chiron Vaccines]

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2005

At a glance

  • Drugs HIV gp120 vaccine; HIV vaccine; HIV vaccine vCP205
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top